Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Zymeworks Inc. (ZYME)
Last zymeworks inc. earnings: 3/2 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.zymeworks.com/overview
Company Research
Source: GlobeNewswire
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327, exhibits anti-tumor activity and a favorable pharmacokinetics profile in Ly6E-bearing cancers VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the acceptance of six abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting being held April 24-30, 2025 in Chicago, IL. “As our wholly-owned pipeline continues to progress, we are excited to share updates at AACR on our novel multifunctional therapeutics addressing difficult-to-treat cancers,” sai
Show less
Read more
Impact Snapshot
Event Time:
ZYME
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZYME alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZYME alerts
High impacting Zymeworks Inc. news events
Weekly update
A roundup of the hottest topics
ZYME
News
- Zymeworks (NASDAQ:ZYME) was upgraded by analysts at Wells Fargo & Company from a "hold" rating to a "strong-buy" rating.MarketBeat
- Zymeworks (NYSE:ZYME) was upgraded by analysts at Wells Fargo & Company from a "cautious" rating to an "overweight" rating.MarketBeat
- Zymeworks (NASDAQ:ZYME) was upgraded by analysts at Citizens Jmp to a "strong-buy" rating.MarketBeat
- Zymeworks (NYSE:ZYME) is now covered by analysts at Citizens Jmp. They set an "outperform" rating and a $32.00 price target on the stock.MarketBeat
- Zymeworks (NYSE:ZYME) was given a new $32.00 price target on by analysts at JMP Securities.MarketBeat
ZYME
Earnings
- 11/6/25 - Beat
ZYME
Sec Filings
- 11/24/25 - Form 144
- 11/21/25 - Form 144
- 11/19/25 - Form SCHEDULE
- ZYME's page on the SEC website